Immune globulin 16.5% - Octapharma

Drug Profile

Immune globulin 16.5% - Octapharma

Alternative Names: Gammanorm; Octanorm

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Developer Aarhus Universitetshospital; Octapharma; Rigshospitalet
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Chronic inflammatory demyelinating polyradiculoneuropathy in Denmark (SC)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Motor-neuron-disease in Denmark (SC)
  • 01 Jul 2016 Octapharma plans the observational Immunorm clinical trial for Autoimmune disorders in France (SC) (ISRCTN32265704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top